Dimerix (ASX:DXB) buys DMX-652 and quietly rebuilds its story

A Phase 2-ready acute kidney injury asset gives DXB a second shot after the ACTION3 timeline blew out.

Dimerix (ASX:DXB) has done something its share register has been quietly asking for since the ACTION3 timeline was pushed out to 2028. It has stopped being a single-asset biotech.

The company announced today that it has acquired DMX-652, a Phase 2-ready acute kidney injury asset, from UK-based Mission Therapeutics. The upfront cost is US$5 million, with up to US$47 million in deferred milestone payments tied to clinical progress, another US$40 million on marketing approval and up to US$175 million in sales milestones after that.

For a company that fell 40% earlier this year when investors realised there would be no accelerated approval on DMX-200, this is a meaningful pivot. Dimerix now has two shots on goal in kidney disease, and the second one comes with an open US IND, a completed 85-patient Phase 1 safety package and an FDA-cleared Phase 2 protocol.

The market read is more nuanced than the deal terms suggest. Dimerix is buying back the optionality it lost when the accelerated approval pathway was abandoned.

The strategic logic behind buying an off-the-shelf Phase 2 program

DMX-652 is a small molecule oral capsule that inhibits USP30, a mitochondrial enzyme involved in clearing damaged mitochondria from injured kidney cells. In plain English, it helps kidney cells recover after the kind of oxygen deprivation that happens during cardiac surgery.

The first Phase 2 indication is cardiac surgery-associated AKI, a condition with no approved therapies and roughly 100,000 to 133,000 US patients a year. Mission has already put DMX-652 through 85 healthy volunteers with no serious drug-related adverse events, and the FDA has cleared the Phase 2 protocol.

Our take is that the real value here is not the AKI market size number, which every biotech deck inflates. It is that Dimerix has bought a de-risked, regulator-blessed program at a stage most companies pay ten times more to reach.

Why the funding structure tells you management is not diluting into this

Management was careful to signpost that the upfront payment, ACTION3 completion and Phase 2 initiation are all fully funded. Sources include existing cash, an A$14 million upfront from Everest Medicines for Asian commercial rights and A$10 million from a binding loan facility Dimerix can draw at its discretion.

Talks are also progressing on up to A$40 million more in non-dilutive funding on similar terms. After the pain of the ACTION3 delay, an equity raise at current levels would have compounded the damage. Management appears to have deliberately avoided that path.

How this changes the catalyst calendar between now and 2028

Before today, the Dimerix investment case was essentially one event, the ACTION3 readout, with a final patient dose in March 2028 and a filing not before 2029. The catalyst gap was the whole problem. Investors do not get paid to wait in silence.

DMX-652 changes that calendar. Ethics approval and site initiation are targeted for the second half of this year, first patient dosing in the first half of 2027 and an interim data readout during 2027. That is a legitimate value-inflection event roughly 12 to 18 months before ACTION3.

The Investors Takeaway for Dimerix

The honest answer to whether this rebuilds the lost optionality is partly. A Phase 2 readout in a first-in-class program is not the same as an accelerated approval on a fully recruited Phase 3, but it is a real catalyst investors can price. Combined with a funding stack that avoids near-term dilution, Dimerix has done more today than most single-asset biotechs manage in a year of damage control.

The question from here is execution. Running cardiac surgery-associated AKI trials across multiple sites and delivering a clean interim readout in 2027 is not trivial. Investors can read our earlier take on the ACTION3 sell-off at stocksdownunder, which explains why the reaction was about timing rather than science.